Originally published In Press as doi:10.1074/jbc.M110275200 on February 1, 2002
J. Biol. Chem., Vol. 277, Issue 20, 17544-17547, May 17, 2002
Selection and Identification of Dense Granule Antigen GRA3 by
Toxoplasma gondii Whole Genome Phage Display*
Johan
Robben
,
Kirsten
Hertveldt
§,
Eugène
Bosmans¶, and
Guido
Volckaert
From the
Laboratory of Gene Technology, Katholieke
Universiteit Leuven, Kasteelpark Arenberg 21, B-3001 Leuven, Belgium
and ¶ DiaMed Eurogen, Transportstraat 4, B-3980 Tessenderlo, Belgium
Received for publication, October 25, 2001, and in revised form, January 24, 2002
 |
ABSTRACT |
Toxoplasma gondii is a ubiquitous,
unicellular, eukaryotic parasite with a complex intracellular life
cycle capable of invading and chronically infecting a wide variety of
vertebrate host species, including man. Although normally opportunistic
in healthy adults, it is a lethal pathogen in immunocompromised humans,
particularly in AIDS patients. We present the application of a genomic
phage display as a tool for the direct identification of antigens with potential value in diagnosis and/or as subunit vaccine components. Using a polycosmid cloning strategy, we constructed a large phagemid display library (>109 independent clones) of mixed short
genomic restriction fragments (
500 bp) of T. gondii
genomic DNA (80 Mbp genome size) fused to gene III of the filamentous
phage M13. Biopanning of the library with monoclonal
Toxoplasma antibodies resulted in the isolation and
identification of an epitope of GRA3, an antigen located in the dense
granules of T. gondii tachyzoites. The reactivity of the
phage displaying the GRA3 epitope with the monoclonal antibody was
confirmed by an enzyme-linked immunosorbent assay. These results demonstrate the accessibility of midsized eukaryotic genomes to display technology and the feasibility to screen these whole
genome display libraries with antibodies for isolating novel antigenic determinants.
 |
INTRODUCTION |
Toxoplasma gondii is an obligate intracellular
protozoan parasite with a complex life cycle (1). Humans usually
acquire infection by ingesting either infectious oocysts through
contact with cats or cat faeces or by eating meat that contains tissue cysts. In healthy adults, infection normally results in a benign self-limiting disease. However, once infected the host harbors the
parasite for life. In a chronically infected individual developing immunodeficiency on response to drug treatment or disease,
e.g. AIDS, the infection can reactivate and cause severe
disease and mortality (2). A primary infection during pregnancy can
cause abortion or severe damage to the fetus. In animals, toxoplasmosis is recognized as a major cause of abortion and neonatal losses in
sheep, goats, and pigs (3).
A diagnosis of toxoplasmosis is usually based on serological assays,
although in recent years molecular biology techniques such as PCR have
been applied for the detection of T. gondii DNA in clinical
samples (4). Most commercial serological assays detect antibodies by
means of natural tachyzoite antigens from infected mice or cell culture
systems. However, the use of whole tachyzoite antigens is rather
expensive and sometimes results in false positive reactions (5). The
use of recombinant antigens may overcome these drawbacks. Until now,
only a limited number of recombinant antigens have been studied,
e.g. the surface antigens SAG1 (P30) (6) and SAG2 (P22) (7),
the dense granule antigens GRA21 (8) and GRA4 (9), and
the rhoptry protein ROP2 (10).
Direct procedures by immunization with non-living vaccines are not as
yet available for humans. Various attempts to develop an animal vaccine
to both the asexual systemic stage and the sexual entero-epithelial
stage of the Toxoplasma life cycle have been reported over
the last thirty years. Immunizations with whole killed (11) or
irradiated (12) parasites had limited success. Effective vaccines have
been produced using live attenuated parasites that induce immunity but
do not persist as tissue cysts (13). Vaccination with pure native P30
antigen (14) or with selected fractions of parasite lysates (15) has
been partially successful. Attempts with recombinant antigens, however,
have failed so far (16).
Further immunological characterization of the Toxoplasma
parasite deserves undiminished attention. The search for new antigens by cDNA screening as well as EST sequencing (17) is hampered by the
complex life cycle and the limited availability of certain parasite
developmental stages. In this paper, we present the application of the
phage display of peptides encoded by fragmented genomic DNA as a useful
tool to directly select and identify antigenic determinants from the
genome. To facilitate the construction of essentially large genomic
libraries, a novel display vector was constructed to allow highly
efficient cloning. The feasibility of this approach was confirmed by
the isolation and identification of an epitope from the dense granule
antigen GRA3 (18) by the panning of a genomic T. gondii
display library against a monoclonal antibody directed toward an
uncharacterized 30-kDa T. gondii antigenic protein.
 |
EXPERIMENTAL PROCEDURES |
Preparation of T. gondii Genomic DNA--
The T. gondii strain Deelen (19) was maintained in permanent in
vitro cultures by serial 3-4 day passages of parasites on monolayers of VERO cells in Opti-MEM medium (Invitrogen)
supplemented with 4% fetal calf serum and 50 µg/ml gentamicin. After
lysis of the monolayer, parasites were harvested by centrifugation of the supernatant. Pellets were resuspended in 1 ml of PBS buffer (phosphate, 0.01 M; NaCl, 0.14 M;
pH 7.2), and the remaining unlysed host cells were ruptured by repeated
forced passage through a 27-gauge needle. The suspension was further
purified by continuous density gradient centrifugation on 36% of
Percoll® (Amersham Biosciences) at 28.600 × g in a
fixed angle 25° rotor. Batches of 109 purified tachyzoite
cells in 100 µl of PBS were lysed by the addition of 1 ml of Qiagen
lysis buffer G2 (Qiagen GmbH, Hilden, Germany) supplemented with 0.5 mg/ml proteinase K and 0.3 mg/ml RNase A and heated at 50 °C for 45 min. Genomic DNA was prepared from the lysate with Qiagen genomic tip
100/G according to the supplier's instructions.
Display Vector Construction--
To create a phagemid display
vector with cosmid properties, the phage lambda cos site
from position
201 to +186 (20) was amplified by PCR with a forward
primer extended at the 5'-end with an AatII and a
BstXI site and a reverse primer bearing an AatII
and a BstEII. The resulting PCR fragment was cloned into the
AatII site of the phagemid vector pHEN1 (21). A number of clones containing the insert in different orientations were
sequence-verified and tested for transducibility after in
vitro packaging of concatamers or so-called polycosmids in phage
lambda particles. Therefore, the vector was linearized with
BstEII, religated at a high vector concentration (500 ng/µl), and mixed with MaxPlaxTM Packaging Extract (Epicentre
Technologies, Madison, WI). Phage particles were titered by the
transduction of Escherichia coli strain TG1 (supE
hsd
5 thi
(lac-proAB) F'{traD36
proAB+ lacIq
lacZ
M15}). One positive clone was retained, and the
phagemid/cosmid vector was termed the phosmid
pHOS1. In this vector, multiple cloning sites (BglII,
SmaI and BstBI) for gene III fusion were created
by the replacement/insertion of a synthetic
NcoI/NotI cassette. Shotgun cloning of
restriction fragments in the correct reading frame was made possible by
the construction of a set of nine phosmids (pHOS21-pHOS29), each with
the multiple cloning sites in a different upstream/downstream gene III
reading frame (Table I).
Genomic Library Construction--
T. gondii genomic
DNA was cut with the four compatible restriction enzymes
HinPI (G
CGC), MspI (C
CGG), AciI
(C
CGC), and TaqI (T
CGA). Equal portions of
genomic DNA were subjected to separate digestions or to consecutive
double, triple, or quadruple digestions in all 15 possible
combinations. The restriction fragments were pooled and fractionated
according to size by preparative electrophoresis through a 10-cm 2.5%
agarose column on a model 230A HPEC System (Applied Biosystems,
Foster City, CA). Nine different size fractions ranging from 30 to 540 bp were selected and concentrated with Microcon YM-10 centrifugal
devices (Millipore, Bedford, MA) prior to ligation into the display
vector. This display vector was prepared by mixing equimolar amounts of
the nine plasmids from the pHOS20 series and by digestion with
BstBI (TT
CGAA) followed by dephosphorylation. The vector
and individual genomic DNA size fractions were ligated at a 1:2 molar
ratio and a low total DNA concentration (~12.5 ng/µl). The
heat-inactivated ligation mixtures were pooled, linearized with
BstEII, and religated at a high concentration (~250
ng/µl). Five fractions of 1 µg of concatenated DNA were packaged in
phage lambda particles and transduced in a single reaction to E. coli TG1 cells grown in LB supplemented with 0.2% maltose and 10 mM MgCl2. In vivo excision of the
vector monomers was realized by co-infection with excess VCSM13 helper
phage (Stratagene, La Jolla, CA). The primary library was obtained by
the collection of phage particles produced 3 h after co-infection.
The number of independent clones was estimated at
109 (see also "Results"). Representative portions of
this library were stored at
70 °C and amplified prior to biopanning.
Biopanning--
Toxoplasma-specific monoclonal
antibodies were obtained from a mouse immunized with sonicated
tachyzoites. Phage amplification, expression, and display of cloned
fragments were performed as described previously (21). The library was
biopanned against Toxoplasma antibodies essentially as
described by Smith and Scott (22). Briefly, in the first selection
round 1012 colony-forming unit phagemid particles
(~1000 times the estimated library size) were allowed to react
overnight at 4 °C with 1 µM biotinylated monoclonal
antibodies preincubated with M13mp18 particles. Binding phagemid
particles were captured for 10 min on 60-mm streptavidin-coated polystyrene Petri dishes blocked with 10% dialyzed fetal calf serum
and 0.02% NaN3 in Tris-buffered saline. After ten washing steps, binding phages were eluted with Tris-glycine, pH 2.2, neutralized, and used for the infection of TG1 cells. Recovered phage
particles in general titered to ~107-8 colony-forming
units. In further rounds, 1-5 × 1011 amplified
phagemid particles were biopanned with monoclonal antibodies at 100 pM.
Selected clones were characterized by automated fluorescent DNA
sequencing on an ABI 373 Sequencer using BigDye TerminatorTM chemistry
(Applied Biosystems). Binding specificity was confirmed by phage ELISA.
Microtiter plates were coated overnight with 500 ng/well specific
monoclonal antibody in PBS and blocked for 2 h with 200 µl/well
blocking buffer (PBS supplemented with 5% bovine serum albumin and
0.02% NaN3). After three washes with PBS and 0.5% Tween
20, about 2 × 1010 phages in 100 µl blocking
solution were allowed to react for 3-4 h. Bound phages were revealed
by a 1-h incubation with secondary horse radish peroxidase-conjugated
anti-M13 antibodies (Amersham Biosciences) and a 30-min staining with
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid). The
difference between A405 and
A495 was taken as the ELISA signal.
 |
RESULTS |
Library Construction--
T. gondii genomic DNA
was semirandomly fragmented by combinatorial digestion with four
restriction enzymes generating protruding 5'-CG ends compatible with
the BstBI cloning site of the pHOS vector set. Size
fractionation by HPEC of the pooled restriction fragments and
A260 monitoring of the eluted DNA showed
a statistically expected asymmetrical size distribution with a peak
around 100 bp and more than 90% of the total DNA contained within
fragments shorter than 500 bp. The 30 to 540 bp fragments were cloned
by phage lambda-mediated polycosmid transduction as described under "Experimental Procedures." The packaged polycosmids were titered at
1.4 × 108 transducing units in total from ~5 µg
of ligated DNA. According to the size of the phosmid (5 kb),
concatamers of 8-10 vector units are expected to be packaged into
lambda particles and transduced into E. coli cells. We could
indeed show the presence of up to 8-10 vectors by PCR analysis of the
cloned inserts in overnight colonies from control-transduced cells not
co-infected with M13 helper phage (Fig.
1). Co-infection resulted as expected in
in vivo excision and packaging of the phagemid monomers into
M13 particles (PCR analysis results not shown). Hence, the total number of independent phagemid clones produced after in vivo
excision was estimated at 1.1-1.4 × 109. The total
number of phagemid particles in the primary library had a titer of
4 × 1011 colony-forming units. PCR analysis of the
whole library and of individual clones confirmed the targeted size
distribution of cloned fragments and showed that less than 5% of the
clones were without insert.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 1.
PCR analysis of Toxoplasma
genomic fragment cloning by polycosmid transduction in the
absence of excision helper phage. Clones were subjected to
standard PCR with vector primers and reaction products analyzed by 2%
agarose electrophoresis. Amplified vector sequence corresponds to
197 ± 2 bp. Multiple bands reflect the presence of up to 10 vectors with different inserts per cell line.
|
|
Clonal representation of the library was evaluated by PCR on plasmid
DNA prepared from an amplified whole library using a set of 12 primers
specific to sequences of the T. gondii P22 and P30 genes.
All primer pairs located on a single, potentially cloned restriction
fragment produced PCR products of the expected size. Primer pairs not
located on potentially cloned restriction fragments yielded PCR
products from genomic control DNA but not from library DNA (data not
shown). Because the library was analyzed after supplementary reinfection with M13 helper phages and phage rescue, we presume that
the possible loss of clones from the library due to the supplementary amplification step had no significant influence on clonal representation.
Biopanning--
The library was biopanned against monoclonal
antibody 2F2, directed against a 30-kDa tachyzoite antigen as
determined by Western blotting, and originally presumed to correspond
to the major surface antigen P30. DNA sequence analysis of 24 individual clones randomly picked from the library obtained after three
selection rounds showed that all selected DNA fragments were inserted
in the correct gene III reading frame and consequently displayed as a
peptide-g3p fusion (Table I). One
sequence occurred 16 times out of 24 random clones and encoded a
peptide of 42 amino acids (Table II).
Sequence similarity search in the public sequence data bases
showed that the peptide corresponds to a segment of the GRA3 protein of
T. gondii (Fig. 2). The
sequence of the cloned DNA fragment is identical to the published
cDNA sequence (18) with the exception of a T > G, resulting
in a Gly instead of a Cys in position 80 of GRA3. In addition, 28 highly significant matches with tachyzoite and bradyzoite cDNA
clones were found in the GenBankTM EST data base division
(Release 041400; 10,741 entries for Toxoplasma). ESTs
overlapping with GRA3 residue 80 all encode for Gly at this position in
strains RH and ME49 in agreement with our sequence. The specificity of
monoclonal antibody 2F2 for the GRA3 epitope was confirmed by phage
ELISA. Restriction analysis of the GRA3 cDNA showed that the panned
fragment corresponded to an AciI fragment, the smallest
epitope encoding fragment potentially present in the genomic
library.
View this table:
[in this window]
[in a new window]
|
Table II
Clones isolated from the Toxoplasma genome phage display library after
three biopanning rounds against monoclonal antibody 2F2
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Sequence alignment of the deduced amino acids
of the monoclonal antibody 2F2-binding peptide obtained by genomic
biopanning with the Toxoplasma GRA3 protein
(Swiss-Prot accession no. Q27914). Discrepant amino acids are in
boldface.
|
|
 |
DISCUSSION |
We have developed an approach to screen for novel antigenic
determinants based on the display of genomic DNA fragment-encoded peptides on filamentous phage. The procedure allows the enrichment of
relevant peptides from the library by affinity selection with specific
antibodies as well as the identification of its corresponding genomic
sequence. The whole genome phage display approach extends display
procedures previously used for epitope mapping (e.g. Refs. 23 and 24). In the latter cases, a single gene, cDNA, or whole plasmid containing the cloned target gene is fragmented with DNaseI, and the resultant clone library is biopanned against monoclonal antibodies. Jacobsson and Frykberg (25) were the first to use genomic
display libraries prepared from sonicated genomic DNA of
Staphylococcus aureus to screen for ligand-binding bacterial receptors. Recently, Lin and Lis (26) applied a randomly sheared yeast
genomic library expressing protein fragments on the surface of lambda
phages for the identification of proteins that interact with the heat
shock factor repression region. This genomic phage display for the
purpose of tracing antigenic determinants of T. gondii is
the first display application on a midsized eukaryotic genome,
expanding the display selection range by an order of magnitude and
dealing with the occurrence of introns.
Statistical analysis of the size distribution of the exons in known
T. gondii genes containing introns indicated that the exons
are often rather short (50-200 bp). These data indicate the need to
include fragments shorter than 100 bp in the library. In contrast,
antibodies recognizing conformational epitopes require the
incorporation of larger fragments encoding peptides capable of adopting
native-like three-dimensional structures (e.g. domains). Large fragments, on the other hand, may include the gene stop codon and
thus be unsuitable for display in N-terminal g3p fusion-based systems.
Hence, a fragment size range from 50 to 500 bp was assumed as most
appropriate. Taking into account a genome size of 80 Mbp (27) and a
one-eighteenth chance of insertion of coding sequences in the correct
orientation and reading frames, a representative library of short
genomic T. gondii fragments should contain
108
independent clones. We preferred to use enzymatic restriction as a DNA
fragmentation method to maximize cloning efficiency. The combinatorial
use of four different tetranucleotide-recognizing restriction enzymes
all generating 5'-CG ends allowed for the generation of short
overlapping DNA fragments and the presence of a given amino acid
sequence in peptides of different lengths in the display library. This
will theoretically increase the chance that an epitope is expressed and
recognized by antibodies. A drawback of the use of restriction cleavage
for fragmentation as opposed to mechanical shearing is the fixed and
reduced resolution of the fragment library. Possible effects of
non-random distribution of CG dinucleotide sequences and the inhibitory
effects of methylation upon restriction fragmentation cannot be
evaluated at present because of insufficient data on the
Toxoplasma genome. Experimental analysis of the restriction
fragment distribution, however, showed that by far most of the
fragments fell within the preferred size range of 50-500 bp.
To accomplish the desired library size, we developed a highly efficient
cloning strategy building on the observation that empty vectors and
cosmids/phosmids with small inserts can tandemly ligate into so-called
polycosmids of appropriate length, packagable into phage lambda
particles. As such, phosmid vectors can be transduced very efficiently
and subsequently rescued successfully in the form of M13-packaged
monomers by M13 helper phage infection. The method is fast, simple, and
easily applicable on a large scale, facilitating the construction of
extremely large libraries. A related system was described for the
efficient construction of phage libraries by lambda-mediated
transduction of cos-engineered M13 phage vectors that are
autonomously released from their concatamers (28). Our approach with
phagemid vectors and helper phage-mediated excision allows us to
increase the total number of vectors packaged from about 6-10 units
per phage head. SurfZAPTM (29) and lambdaZLG6 (30) are other examples
of phage display systems taking advantage of the cloning
efficiency of phage lambda. In these systems, however, only a single
phagemid is subjected to in vivo excision.
The proof of principle was delivered by biopanning of the constructed
T. gondii genomic display library against monoclonal antibodies obtained by the immunization of mice with sonicated tachyzoites. After three selection rounds, almost exclusive enrichment was observed of clones containing an open reading frame correctly fused
to gene III. One clone occurred in excess (67%). A sequence similarity
search of the encoded peptide in public protein data bases revealed the
identity with a segment of the T. gondii GRA3 protein. GRA3
is a 220-amino acid protein with a mature molecular weight of 30 kDa
(18) and belongs to a group of antigenic proteins located in the dense
granules of tachyzoites. Hence, the identified 30-kDa antigen was not
the abundantly expressed p30 surface antigen (SAG1) initially presumed
to react with the monoclonal antibody in Western blots of total
tachyzoite proteins but a different highly expressed (17) tachyzoite
protein. GRA proteins are secreted into the tachyzoite parasitophorous
vacuole after invasion of the host cell and are also found in the
parasitophorous vacuole membrane and in the bradyzoite cyst wall. Dense
granule antigens are recognized by an important fraction of the
specific G, M, and A immunoglobulins in the serum of patients suffering
from acute toxoplasmosis (31).
The isolation of the GRA3 gene fragment by biopanning confirmed the
feasibility of the use of phage display to screen randomized genomic
expression libraries with antibodies for novel antigen genes. Because
only protein fragments are displayed, the approach is expected to be
most appropriate for biopanning against antibodies recognizing linear
epitopes, although the discovery of non-linear epitopes may not be
impossible. Whether the genomic display approach is also amenable to
biopanning with polyclonal antibodies remains to be investigated.
 |
ACKNOWLEDGEMENT |
We thank Janick Mathys for useful discussions
and critical reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported by the Flemish Biotechnology Action
Program (Vlaams Actieprogramma Biotechnologie, VLAB).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a predoctoral fellowship from the Fonds voor
Wetenschappelijk Onderzoek Vlaanderen (FWO).
To whom correspondence should be addressed. Tel.:
32-16-329669; Fax: 32-16-321965; E-mail:
guido.volckaert@agr.kuleuven.ac.be.
Published, JBC Papers in Press, February 1, 2002, DOI 10.1074/jbc.M110275200
 |
ABBREVIATIONS |
The abbreviations used are:
GRA, granule
antigen;
EST, expressed sequence tag;
PBS, phosphate-buffered saline;
ELISA, enzyme-linked immunosorbent assay.
 |
REFERENCES |
| 1.
|
Black, M. W.,
and Boothroyd, J. C.
(2000)
Microbiol. Mol. Biol. Rev.
64,
607-623[Abstract/Free Full Text]
|
| 2.
|
Wong, S. Y.,
and Remington, J. S.
(1993)
AIDS
7,
299-316[Medline]
[Order article via Infotrieve]
|
| 3.
|
Buxton, D.
(1998)
Vet. Res. (Paris)
29,
289-310[Medline]
[Order article via Infotrieve]
|
| 4.
|
Pelloux, H.,
Dupouy-Camet, J.,
Derouin, F.,
Aboulker, J. P.,
and Raffi, F.
(1997)
AIDS
11,
1888-1890[Medline]
[Order article via Infotrieve]
|
| 5.
|
Taylor, D. W.,
Evans, C. B.,
Aley, S. B.,
Barta, J. R.,
and Danforth, H. D.
(1990)
J. Protozool.
37,
540-545[Medline]
[Order article via Infotrieve]
|
| 6.
|
Kim, K.,
Bulow, R.,
Kampmeier, J.,
and Boothroyd, J. C.
(1994)
Infect. Immun.
62,
203-209[Abstract/Free Full Text]
|
| 7.
|
Parmley, S. F.,
Sgarlato, G. D.,
Mark, J.,
Prince, J. B.,
and Remington, J. S.
(1992)
J. Clin. Microbiol.
30,
1127-1133[Abstract/Free Full Text]
|
| 8.
|
Murray, A.,
Mercier, C.,
Decoster, A.,
Lecordier, L.,
Capron, A.,
and Cesbron-Delauw, M. F.
(1993)
Appl. Parasitol.
34,
235-244[Medline]
[Order article via Infotrieve]
|
| 9.
|
Mevelec, M. N.,
Chardes, T.,
Mercereau-Puijalon, O.,
Bourguin, I.,
Achbarou, A.,
Dubremetz, J. F.,
and Bout, D.
(1992)
Mol. Biochem. Parasitol.
56,
227-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Martin, V.,
Arcavi, M.,
Santillan, G.,
Amendoeira, M. R., De,
Souza Neves, E.,
Griemberg, G.,
Guarnera, E.,
Garberi, J. C.,
and Angel, S. O.
(1998)
Clin. Diagn. Lab. Immunol.
5,
627-631[Abstract/Free Full Text]
|
| 11.
|
Frenkel, J. K.,
and Smith, D. D.
(1982)
J. Parasitol.
68,
744-748[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Seah, S. K.,
and Hucal, G.
(1975)
Can. J. Microbiol.
21,
1379-1385[Medline]
[Order article via Infotrieve]
|
| 13.
|
Buxton, D.,
and Innes, E. A.
(1995)
Parasitology
110,
S11-S16
|
| 14.
|
Bulow, R.,
and Boothroyd, J.
(1991)
J. Immunol.
147,
3496-3500[Abstract]
|
| 15.
|
Lunden, A.,
Lovgren, K.,
Uggla, A.,
and Araujo, F. G.
(1993)
Infect. Immun.
61,
2639-2643[Abstract/Free Full Text]
|
| 16.
|
Lunden, A.,
Parmley, S. F.,
Bengtsson, K. L.,
and Araujo, F. G.
(1997)
Parasitol. Res.
83,
6-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Ajioka, J. W.,
Boothroyd, J. C.,
Brunk, B. P.,
Hehl, A.,
Hillier, L.,
Manger, I. D.,
Marra, M.,
Overton, G. C.,
Roos, D. S.,
Wan, K. L.,
Waterston, R.,
and Sibley, L. D.
(1998)
Genome Res.
8,
18-28[Abstract/Free Full Text]
|
| 18.
|
Bermudes, D.,
Dubremetz, J. F.,
Achbarou, A.,
and Joiner, K. A.
(1994)
Mol. Biochem. Parasitol.
68,
247-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
van Loon, A. M.,
and van der Veen, J.
(1980)
J. Comp. Pathol.
33,
635-639
|
| 20.
|
Hohn, B.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
7456-7460[Abstract/Free Full Text]
|
| 21.
|
Hoogenboom, H. R.,
Griffiths, A. D.,
Johnson, K. S.,
Chiswell, D. J.,
Hudson, P.,
and Winter, G.
(1991)
Nucleic Acids Res.
19,
4133-4137[Abstract/Free Full Text]
|
| 22.
|
Smith, G. P.,
and Scott, J. K.
(1993)
Methods Enzymol.
217,
228-257[Medline]
[Order article via Infotrieve]
|
| 23.
|
Wang, L. F., Du,
Plessis, D. H.,
White, J. R.,
Hyatt, A. D.,
and Eaton, B. T.
(1995)
J. Immunol. Methods
178,
1-12[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Petersen, G.,
Song, D.,
Hugle-Dorr, B.,
Oldenburg, I.,
and Bautz, E. K.
(1995)
Mol. Gen. Genet.
249,
425-431[Medline]
[Order article via Infotrieve]
|
| 25.
|
Jacobsson, K.,
and Frykberg, L.
(1995)
BioTechniques
18,
878-885[Medline]
[Order article via Infotrieve]
|
| 26.
|
Lin, J. T.,
and Lis, J. T.
(1999)
Mol. Cell. Biol.
19,
3237-3245[Abstract/Free Full Text]
|
| 27.
|
Sibley, L. D.,
and Boothroyd, J. C.
(1992)
Mol. Biochem. Parasitol.
51,
291-300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Alting-Mees, M. A.,
and Short, J. M.
(1993)
Gene (Amst.)
137,
93-100[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Hogrefe, H. H.,
Amberg, J. R.,
Hay, B. N.,
Sorge, J. A.,
and Shopes, B.
(1993)
Gene (Amst.)
137,
85-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Jespers, L. S., De,
Keyser, A.,
and Stanssens, E.
(1996)
Gene (Amst.)
173,
179-181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Kumolosasi, E.,
Bonhomme, A.,
Beorchia, A.,
Lepan, H.,
Marx, C.,
Foudrinier, F.,
Pluot, M.,
and Pinon, J. M.
(1994)
Microsc. Res. Tech.
29,
231-239[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.